Comparative study on the efficacy of sulbactam·ampicillin and ampicillin in respiratory tract infections

Kotaro Oizumi; Akira Saito; Akira Suzuki; Yohmei Hiraga; Kazuo Takebe; Masao Tamura; Hiroyuki Kobayashi; Atsushi Saito; Ippei Fujimori; Fumio Miki; Rinzo Soejima; Kohei Hara; Keizo Matsumoto; Kiyoshi Konno; Akihiko Homma; Matsumi Tosaka; Tomofumi Igarashi; Katsunori Kasahara; Sohkichi Onodera; Nobuhiro Sasaki; Yuji Ikeda; Akira Saito; Akira Suzuki; Yasuto Honnda; Masumi Tomizawa; Yohmei Hiraga; Mituhide Ohmichi; Ichiro Nakayama; Akio Hirayama; Susumu Isokawa; Kyuichiro Sekine; Susumu Itoh; Hirotoshi Nishizawa; Morikuni Abe; Choei Itoh; Keisuke Takeuchi; Hajime Watanabe; Tsuyoshi Kikuiri; Tadashi Murakami; Kazuo Takebe; Katsuhiro Okamoto; Morio Sagara; Toyoichi Tamura; Katsumi Endoh; Masashi Yoneda; Osamu Uehara; Tadashi Miyasawa; Mitsuo Nakamura; Kiyoshi Kawamorita; Masao Tamura; Takashi Itoh; Nobuhisa Satoh; Kazuo Tanifuji; Hiroshi Kuramistu; Kohtaro Itakura; Tsukasa Yoshida; Masayuki Yoshizawa; Mamoru Furuta; Masato Hayashi; Kazuo Satoh; Kiichi Kaishio; Noboru Asabu; Saburo Shindoh; Kohsaku Nagai; Kiyoshi Konno; Kotaro Oizumi; Akira Watanabe; Hiroyuki Nakai; Junichi Saito; Tokuji Honda; Fumio Ariji; Teruo Hasuike; Moriaki Nishina; Masayuki Itoh; Shigeru Tamari; Eiju Umehara; Izumi Hayashi; Tsuguji Itoh; Yoshiyuki Ando; Yasushi Ueda; Atsushi Saito; Tadashi Miyahara; Hiroyuki Kobayashi; Yasuyuki Sano; Yasufumi Miyamoto; Ippei Fujimori; Yoshio Kobayashi; Shigeo Takizawa; Fumio Miki; Rinzo Soejima; Yoshihito Niki; Toshiro Oda; Kohei Hara; Keizo Matsumoto; Toshiaki Hayashi; Harumi Shishido; Kaoru Shimada; Mieko Gotoh; Nobuya Ogawa

doi:10.11250/chemotherapy1953.36.Supplement8_272

Comparative study on the efficacy of sulbactam·ampicillin and ampicillin in respiratory tract infections

Kotaro Oizumi, Akira Saito, Akira Suzuki, Yohmei Hiraga, Kazuo Takebe, Masao Tamura, Hiroyuki Kobayashi, Atsushi Saito, Ippei Fujimori, Fumio Miki, Rinzo Soejima, Kohei Hara, Keizo Matsumoto, Kiyoshi Konno, Akihiko Homma, Matsumi Tosaka, Tomofumi Igarashi, Katsunori Kasahara, Sohkichi Onodera, Nobuhiro SasakiYuji Ikeda, Akira Saito, Akira Suzuki, Yasuto Honnda, Masumi Tomizawa, Yohmei Hiraga, Mituhide Ohmichi, Ichiro Nakayama, Akio Hirayama, Susumu Isokawa, Kyuichiro Sekine, Susumu Itoh, Hirotoshi Nishizawa, Morikuni Abe, Choei Itoh, Keisuke Takeuchi, Hajime Watanabe, Tsuyoshi Kikuiri, Tadashi Murakami, Kazuo Takebe, Katsuhiro Okamoto, Morio Sagara, Toyoichi Tamura, Katsumi Endoh, Masashi Yoneda, Osamu Uehara, Tadashi Miyasawa, Mitsuo Nakamura, Kiyoshi Kawamorita, Masao Tamura, Takashi Itoh, Nobuhisa Satoh, Kazuo Tanifuji, Hiroshi Kuramistu, Kohtaro Itakura, Tsukasa Yoshida, Masayuki Yoshizawa, Mamoru Furuta, Masato Hayashi, Kazuo Satoh, Kiichi Kaishio, Noboru Asabu, Saburo Shindoh, Kohsaku Nagai, Kiyoshi Konno, Kotaro Oizumi, Akira Watanabe, Hiroyuki Nakai, Junichi Saito, Tokuji Honda, Fumio Ariji, Teruo Hasuike, Moriaki Nishina, Masayuki Itoh, Shigeru Tamari, Eiju Umehara, Izumi Hayashi, Tsuguji Itoh, Yoshiyuki Ando, Yasushi Ueda, Atsushi Saito, Tadashi Miyahara, Hiroyuki Kobayashi, Yasuyuki Sano, Yasufumi Miyamoto, Ippei Fujimori, Yoshio Kobayashi, Shigeo Takizawa, Fumio Miki, Rinzo Soejima, Yoshihito Niki, Toshiro Oda, Kohei Hara, Keizo Matsumoto, Toshiaki Hayashi, Harumi Shishido, Kaoru Shimada, Mieko Gotoh, Nobuya Ogawa

Research output: Contribution to journal › Article › peer-review

2 Citations (Scopus)

Abstract

A multi-center double-blind three-group comparison study of sulbactam·ampicillin (SBT·ABPC) vs. ampicillin (ABPC) was performed to evaluate their efficacy, safety and usefulness in the treament of patients with respiratory tract infections. The clinical efficacy rated by Investigators' Judgment Committee was compared among three dosage groups of 3g SBT·ABPC, 6g SBT·ABPC and 4g ABPC. In the patients with pulmonary parenchymal infections, the efficacy rate was 82.5%, 92.1% and 94.6%, respectively. In chronic respiratory tract infections, that rate was 86.7%, 81.6% and 82.1%, respectively. All of these three groups showed excellent efficacy rates, and there were no significant differences among them. The bacterial eradication rate was 93.2%, 83.7% and 85.4% respectively, suggesting that there were no significant differences in the bacteriological efficacy among the three dosage groups. The MICs, determined at a central laboratory, indicated that almost all the strains were sensitive to SBT·ABPC and many to ABPC alone. The MICs of ABPC were 25 μg/ml and above against 13 strains, whereas those of SBT·ABPC were 2-to 5-fold lower. All dosage groups exhibited high usefulness rates with a low incidence of side effects and parameter abnormalities in laboratory tests, suggesting no significant differences in safety and usefulness. The results obtained in this study indicate that SBT·ABPC is useful in the treatment of patients with respiratory tract infections.

Original language	English
Pages (from-to)	272-291
Number of pages	20
Journal	Chemotherapy
Volume	36
DOIs	https://doi.org/10.11250/chemotherapy1953.36.Supplement8_272
Publication status	Published - 1988
Externally published	Yes

ASJC Scopus subject areas

Pharmacology (medical)
Infectious Diseases
Pharmacology
Drug Discovery
Oncology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.11250/chemotherapy1953.36.Supplement8_272

Cite this

Oizumi, K., Saito, A., Suzuki, A., Hiraga, Y., Takebe, K., Tamura, M., Kobayashi, H., Saito, A., Fujimori, I., Miki, F., Soejima, R., Hara, K., Matsumoto, K., Konno, K., Homma, A., Tosaka, M., Igarashi, T., Kasahara, K., Onodera, S., ... Ogawa, N. (1988). Comparative study on the efficacy of sulbactam·ampicillin and ampicillin in respiratory tract infections. Chemotherapy, 36, 272-291. https://doi.org/10.11250/chemotherapy1953.36.Supplement8_272

Oizumi, K, Saito, A, Suzuki, A, Hiraga, Y, Takebe, K, Tamura, M, Kobayashi, H, Saito, A, Fujimori, I, Miki, F, Soejima, R, Hara, K, Matsumoto, K, Konno, K, Homma, A, Tosaka, M, Igarashi, T, Kasahara, K, Onodera, S, Sasaki, N, Ikeda, Y, Saito, A, Suzuki, A, Honnda, Y, Tomizawa, M, Hiraga, Y, Ohmichi, M, Nakayama, I, Hirayama, A, Isokawa, S, Sekine, K, Itoh, S, Nishizawa, H, Abe, M, Itoh, C, Takeuchi, K, Watanabe, H, Kikuiri, T, Murakami, T, Takebe, K, Okamoto, K, Sagara, M, Tamura, T, Endoh, K, Yoneda, M, Uehara, O, Miyasawa, T, Nakamura, M, Kawamorita, K, Tamura, M, Itoh, T, Satoh, N, Tanifuji, K, Kuramistu, H, Itakura, K, Yoshida, T, Yoshizawa, M, Furuta, M, Hayashi, M, Satoh, K, Kaishio, K, Asabu, N, Shindoh, S, Nagai, K, Konno, K, Oizumi, K, Watanabe, A, Nakai, H, Saito, J, Honda, T, Ariji, F, Hasuike, T, Nishina, M, Itoh, M, Tamari, S, Umehara, E, Hayashi, I, Itoh, T, Ando, Y, Ueda, Y, Saito, A, Miyahara, T, Kobayashi, H, Sano, Y, Miyamoto, Y, Fujimori, I, Kobayashi, Y, Takizawa, S, Miki, F, Soejima, R, Niki, Y, Oda, T, Hara, K, Matsumoto, K, Hayashi, T, Shishido, H, Shimada, K, Gotoh, M & Ogawa, N 1988, 'Comparative study on the efficacy of sulbactam·ampicillin and ampicillin in respiratory tract infections', Chemotherapy, vol. 36, pp. 272-291. https://doi.org/10.11250/chemotherapy1953.36.Supplement8_272

@article{68c82ad01a42495794ceaff3089f21d9,

title = "Comparative study on the efficacy of sulbactam·ampicillin and ampicillin in respiratory tract infections",

abstract = "A multi-center double-blind three-group comparison study of sulbactam·ampicillin (SBT·ABPC) vs. ampicillin (ABPC) was performed to evaluate their efficacy, safety and usefulness in the treament of patients with respiratory tract infections. The clinical efficacy rated by Investigators' Judgment Committee was compared among three dosage groups of 3g SBT·ABPC, 6g SBT·ABPC and 4g ABPC. In the patients with pulmonary parenchymal infections, the efficacy rate was 82.5%, 92.1% and 94.6%, respectively. In chronic respiratory tract infections, that rate was 86.7%, 81.6% and 82.1%, respectively. All of these three groups showed excellent efficacy rates, and there were no significant differences among them. The bacterial eradication rate was 93.2%, 83.7% and 85.4% respectively, suggesting that there were no significant differences in the bacteriological efficacy among the three dosage groups. The MICs, determined at a central laboratory, indicated that almost all the strains were sensitive to SBT·ABPC and many to ABPC alone. The MICs of ABPC were 25 μg/ml and above against 13 strains, whereas those of SBT·ABPC were 2-to 5-fold lower. All dosage groups exhibited high usefulness rates with a low incidence of side effects and parameter abnormalities in laboratory tests, suggesting no significant differences in safety and usefulness. The results obtained in this study indicate that SBT·ABPC is useful in the treatment of patients with respiratory tract infections.",

author = "Kotaro Oizumi and Akira Saito and Akira Suzuki and Yohmei Hiraga and Kazuo Takebe and Masao Tamura and Hiroyuki Kobayashi and Atsushi Saito and Ippei Fujimori and Fumio Miki and Rinzo Soejima and Kohei Hara and Keizo Matsumoto and Kiyoshi Konno and Akihiko Homma and Matsumi Tosaka and Tomofumi Igarashi and Katsunori Kasahara and Sohkichi Onodera and Nobuhiro Sasaki and Yuji Ikeda and Akira Saito and Akira Suzuki and Yasuto Honnda and Masumi Tomizawa and Yohmei Hiraga and Mituhide Ohmichi and Ichiro Nakayama and Akio Hirayama and Susumu Isokawa and Kyuichiro Sekine and Susumu Itoh and Hirotoshi Nishizawa and Morikuni Abe and Choei Itoh and Keisuke Takeuchi and Hajime Watanabe and Tsuyoshi Kikuiri and Tadashi Murakami and Kazuo Takebe and Katsuhiro Okamoto and Morio Sagara and Toyoichi Tamura and Katsumi Endoh and Masashi Yoneda and Osamu Uehara and Tadashi Miyasawa and Mitsuo Nakamura and Kiyoshi Kawamorita and Masao Tamura and Takashi Itoh and Nobuhisa Satoh and Kazuo Tanifuji and Hiroshi Kuramistu and Kohtaro Itakura and Tsukasa Yoshida and Masayuki Yoshizawa and Mamoru Furuta and Masato Hayashi and Kazuo Satoh and Kiichi Kaishio and Noboru Asabu and Saburo Shindoh and Kohsaku Nagai and Kiyoshi Konno and Kotaro Oizumi and Akira Watanabe and Hiroyuki Nakai and Junichi Saito and Tokuji Honda and Fumio Ariji and Teruo Hasuike and Moriaki Nishina and Masayuki Itoh and Shigeru Tamari and Eiju Umehara and Izumi Hayashi and Tsuguji Itoh and Yoshiyuki Ando and Yasushi Ueda and Atsushi Saito and Tadashi Miyahara and Hiroyuki Kobayashi and Yasuyuki Sano and Yasufumi Miyamoto and Ippei Fujimori and Yoshio Kobayashi and Shigeo Takizawa and Fumio Miki and Rinzo Soejima and Yoshihito Niki and Toshiro Oda and Kohei Hara and Keizo Matsumoto and Toshiaki Hayashi and Harumi Shishido and Kaoru Shimada and Mieko Gotoh and Nobuya Ogawa",

year = "1988",

doi = "10.11250/chemotherapy1953.36.Supplement8_272",

language = "English",

volume = "36",

pages = "272--291",

journal = "CHEMOTHERAPY",

issn = "0009-3165",

}

TY - JOUR

T1 - Comparative study on the efficacy of sulbactam·ampicillin and ampicillin in respiratory tract infections

AU - Oizumi, Kotaro

AU - Saito, Akira

AU - Suzuki, Akira

AU - Hiraga, Yohmei

AU - Takebe, Kazuo

AU - Tamura, Masao

AU - Kobayashi, Hiroyuki

AU - Saito, Atsushi

AU - Fujimori, Ippei

AU - Miki, Fumio

AU - Soejima, Rinzo

AU - Hara, Kohei

AU - Matsumoto, Keizo

AU - Konno, Kiyoshi

AU - Homma, Akihiko

AU - Tosaka, Matsumi

AU - Igarashi, Tomofumi

AU - Kasahara, Katsunori

AU - Onodera, Sohkichi

AU - Sasaki, Nobuhiro

AU - Ikeda, Yuji

AU - Saito, Akira

AU - Suzuki, Akira

AU - Honnda, Yasuto

AU - Tomizawa, Masumi

AU - Hiraga, Yohmei

AU - Ohmichi, Mituhide

AU - Nakayama, Ichiro

AU - Hirayama, Akio

AU - Isokawa, Susumu

AU - Sekine, Kyuichiro

AU - Itoh, Susumu

AU - Nishizawa, Hirotoshi

AU - Abe, Morikuni

AU - Itoh, Choei

AU - Takeuchi, Keisuke

AU - Watanabe, Hajime

AU - Kikuiri, Tsuyoshi

AU - Murakami, Tadashi

AU - Takebe, Kazuo

AU - Okamoto, Katsuhiro

AU - Sagara, Morio

AU - Tamura, Toyoichi

AU - Endoh, Katsumi

AU - Yoneda, Masashi

AU - Uehara, Osamu

AU - Miyasawa, Tadashi

AU - Nakamura, Mitsuo

AU - Kawamorita, Kiyoshi

AU - Tamura, Masao

AU - Itoh, Takashi

AU - Satoh, Nobuhisa

AU - Tanifuji, Kazuo

AU - Kuramistu, Hiroshi

AU - Itakura, Kohtaro

AU - Yoshida, Tsukasa

AU - Yoshizawa, Masayuki

AU - Furuta, Mamoru

AU - Hayashi, Masato

AU - Satoh, Kazuo

AU - Kaishio, Kiichi

AU - Asabu, Noboru

AU - Shindoh, Saburo

AU - Nagai, Kohsaku

AU - Konno, Kiyoshi

AU - Oizumi, Kotaro

AU - Watanabe, Akira

AU - Nakai, Hiroyuki

AU - Saito, Junichi

AU - Honda, Tokuji

AU - Ariji, Fumio

AU - Hasuike, Teruo

AU - Nishina, Moriaki

AU - Itoh, Masayuki

AU - Tamari, Shigeru

AU - Umehara, Eiju

AU - Hayashi, Izumi

AU - Itoh, Tsuguji

AU - Ando, Yoshiyuki

AU - Ueda, Yasushi

AU - Saito, Atsushi

AU - Miyahara, Tadashi

AU - Kobayashi, Hiroyuki

AU - Sano, Yasuyuki

AU - Miyamoto, Yasufumi

AU - Fujimori, Ippei

AU - Kobayashi, Yoshio

AU - Takizawa, Shigeo

AU - Miki, Fumio

AU - Soejima, Rinzo

AU - Niki, Yoshihito

AU - Oda, Toshiro

AU - Hara, Kohei

AU - Matsumoto, Keizo

AU - Hayashi, Toshiaki

AU - Shishido, Harumi

AU - Shimada, Kaoru

AU - Gotoh, Mieko

AU - Ogawa, Nobuya

PY - 1988

Y1 - 1988

N2 - A multi-center double-blind three-group comparison study of sulbactam·ampicillin (SBT·ABPC) vs. ampicillin (ABPC) was performed to evaluate their efficacy, safety and usefulness in the treament of patients with respiratory tract infections. The clinical efficacy rated by Investigators' Judgment Committee was compared among three dosage groups of 3g SBT·ABPC, 6g SBT·ABPC and 4g ABPC. In the patients with pulmonary parenchymal infections, the efficacy rate was 82.5%, 92.1% and 94.6%, respectively. In chronic respiratory tract infections, that rate was 86.7%, 81.6% and 82.1%, respectively. All of these three groups showed excellent efficacy rates, and there were no significant differences among them. The bacterial eradication rate was 93.2%, 83.7% and 85.4% respectively, suggesting that there were no significant differences in the bacteriological efficacy among the three dosage groups. The MICs, determined at a central laboratory, indicated that almost all the strains were sensitive to SBT·ABPC and many to ABPC alone. The MICs of ABPC were 25 μg/ml and above against 13 strains, whereas those of SBT·ABPC were 2-to 5-fold lower. All dosage groups exhibited high usefulness rates with a low incidence of side effects and parameter abnormalities in laboratory tests, suggesting no significant differences in safety and usefulness. The results obtained in this study indicate that SBT·ABPC is useful in the treatment of patients with respiratory tract infections.

AB - A multi-center double-blind three-group comparison study of sulbactam·ampicillin (SBT·ABPC) vs. ampicillin (ABPC) was performed to evaluate their efficacy, safety and usefulness in the treament of patients with respiratory tract infections. The clinical efficacy rated by Investigators' Judgment Committee was compared among three dosage groups of 3g SBT·ABPC, 6g SBT·ABPC and 4g ABPC. In the patients with pulmonary parenchymal infections, the efficacy rate was 82.5%, 92.1% and 94.6%, respectively. In chronic respiratory tract infections, that rate was 86.7%, 81.6% and 82.1%, respectively. All of these three groups showed excellent efficacy rates, and there were no significant differences among them. The bacterial eradication rate was 93.2%, 83.7% and 85.4% respectively, suggesting that there were no significant differences in the bacteriological efficacy among the three dosage groups. The MICs, determined at a central laboratory, indicated that almost all the strains were sensitive to SBT·ABPC and many to ABPC alone. The MICs of ABPC were 25 μg/ml and above against 13 strains, whereas those of SBT·ABPC were 2-to 5-fold lower. All dosage groups exhibited high usefulness rates with a low incidence of side effects and parameter abnormalities in laboratory tests, suggesting no significant differences in safety and usefulness. The results obtained in this study indicate that SBT·ABPC is useful in the treatment of patients with respiratory tract infections.

UR - http://www.scopus.com/inward/record.url?scp=0024209521&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024209521&partnerID=8YFLogxK

U2 - 10.11250/chemotherapy1953.36.Supplement8_272

DO - 10.11250/chemotherapy1953.36.Supplement8_272

M3 - Article

AN - SCOPUS:0024209521

SN - 0009-3165

VL - 36

SP - 272

EP - 291

JO - CHEMOTHERAPY

JF - CHEMOTHERAPY

ER -

Comparative study on the efficacy of sulbactam·ampicillin and ampicillin in respiratory tract infections

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this